Mitoxantrone Baxter

Mitoxantrone Baxter

mitoxantrone

Manufacturer:

Baxter Healthcare

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Mitoxantrone HCl
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Mammary carcinoma, non-Hodgkin's lymphoma, primary liver cell carcinoma, ovarian carcinoma 14 mg/m2 BSA as initial dose for 1st cycle. Repeat after 21 days. Acute leukemia 10-12 mg/m2 for 5 consecutive days.
Contraindications
Apply w/ caution to patients w/ pancytopenia or severe infections, severe hepatic &/or renal insufficiency, severe heart disease & those previously treated w/ anthracyclines &/or irradiated on mediastinum. Pregnancy & lactation.
Special Precautions
Monitor hematological blood parameters before each application as well as at least once during each treatment cycle. Monitor heart function after cumulative dose of >160 mg/m2 BSA (140 mg/m2 in risky patients) has been reached.
Adverse Reactions
Bone marrow depression, nausea, vomiting, alopecia, transient ECG alteration, acute arrhythmia, reduced left ventricular output, cardiac insufficiency, blue-green urine coloration.
Drug Interactions
Other antineoplastic drugs.
ATC Classification
L01DB07 - mitoxantrone ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Presentation/Packing
Form
Mitoxantrone Baxter inj 10 mg/5 mL
Packing/Price
1's
Form
Mitoxantrone Baxter inj 20 mg/10 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in